Cited 0 times in
MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.